The chart is not accessible to screen readers. Please switch to the table view to access the data.
During the third quarter of 2024, around ** percent of Celltrion's bioproducts revenue stemmed from Remsima IV, an anti-inflammatory used to treat several immune system conditions such as Crohn's disease. The company's bioproducts sector made up the vast majority of its overall revenue that year.
Log in or register to access precise data.
* For commercial use only
Basic Account
Starter Account
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
About the industry
About the region
Selected statistics
Other regions
Related statistics
* For commercial use only
Basic Account
Starter Account
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
